Virtual Meetings 2020

Current Questions and Controversies in the Management of Lung Cancer — A Virtual Meet The Professor Series

Research To Practice (RTP) is pleased to offer community- and academic-based hospitals and cancer centers throughout the United States the opportunity to participate in an online educational activity focused on the management of lung cancer. Each session in this series will feature a blend of didactic presentation, discussion of steering committee members’ treatment recommendations, interactive polling of attendees and follow-up audience Q&A.

If you are interested in hosting a virtual session for your institution, please email our Meeting Services Department at GRTeam@ResearchToPractice.com or call (800) 233-6153.

Each 1-hour session will include 4 topic modules focused on current management, emerging research and novel agents and strategies under active investigation for lung cancer. Each event will employ an identical format that will include the following elements:

  • • Discussion of Steering Committee Members’ Treatment Recommendations
  • • Review of Available Clinical Research Findings
  • • Integration of Interactive Audience Polling Results
MODULE 1 Management of Metastatic Non-Small Cell Lung Cancer (NSCLC) with an EGFR Tumor Mutation MODULE 2 Checkpoint Inhibition in the Management of Locally Advanced NSCLC MODULE 3 Anti-PD-1/PD-L1 Antibodies Alone or in Combinations for Metastatic NSCLC MODULE 4 First-Line Treatment of Extensive-Stage Small Cell Lung Cancer

Each session will conclude with a 5-minute Q&A segment on current clinical care in the age of COVID-19.

Target Audience
This activity is intended for medical oncologists and other healthcare providers involved in the treatment of lung cancer.

Learning Objectives

  • Appreciate available clinical trial findings supporting the use of osimertinib as first-line therapy for patients with non-small cell lung cancer (NSCLC) with an EGFR tumor mutation, including those with CNS metastases, and consider the effect of this information on current and future clinical practice.
  • Review published research data documenting the safety and efficacy of EGFR tyrosine kinase inhibitors in combination with VEGFR-targeted therapy for metastatic NSCLC with an EGFR tumor mutation, and discern the potential ramifications of this information for practice and future clinical trial design.
  • Appraise the FDA approval of anti-PD-L1 antibody consolidation therapy for patients with unresectable Stage III NSCLC who have not experienced disease progression after standard platinum-based chemotherapy concurrent with radiation therapy, and appropriately and safely integrate this strategy into clinical practice.
  • Appraise published research data and current guideline recommendations informing the use of immune checkpoint inhibitors for small cell lung cancer (SCLC), and discern how these agents can be optimally employed in clinical practice.
  • Appreciate available Phase III data investigating the role of durvalumab in combination with platinum-based chemotherapy for newly diagnosed extensive-stage SCLC, and use this information to identify patients who may be appropriate for treatment with this novel approach.
  • Recognize recent FDA approvals and other therapeutic advances related to the use of anti-PD-1/PD-L1 antibodies as monotherapy or in combination with chemotherapy or chemobiologic therapy for newly diagnosed metastatic NSCLC.
  • Evaluate available and emerging research data documenting the efficacy and safety of anti-PD-1/PD-L1 and anti-CTLA-4 antibody combinations with or without chemotherapy as first-line treatment for NSCLC, and consider the potential roles of these regimens.

CME Credit Form
An online CME credit form will be made available to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Commercial Support
These activities are supported by an educational grant from AstraZeneca Pharmaceuticals LP.


STEERING COMMITTEE MEMBERS

John V Heymach, MD, PhD
Professor and Chair
Thoracic/Head and Neck Medical Oncology
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Leora Horn, MD, MSc
Ingram Associate Professor of Cancer Research
Director, Thoracic Oncology Research Program
Assistant Vice Chairman for Faculty Development
Vanderbilt University Medical Center
Nashville, Tennessee

Corey J Langer, MD
Director of Thoracic Oncology
Abramson Cancer Center
Professor of Medicine
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

Benjamin Levy, MD
Associate Professor
Johns Hopkins School of Medicine
Clinical Director
Medical Director, Thoracic Oncology Program
Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial
Washington, DC

Joel W Neal, MD, PhD
Associate Professor of Medicine
Division of Oncology, Department of Medicine
Stanford Cancer Institute
Stanford University
Palo Alto, California

Nathan A Pennell, MD, PhD
Associate Professor
Hematology and Medical Oncology
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Director, Cleveland Clinic Lung Cancer Medical Oncology Program
Cleveland, Ohio

Lecia V Sequist, MD, MPH
Director, Center for Innovation in Early
Cancer Detection
Massachusetts General Hospital Cancer Center
The Landry Family Associate Professor
of Medicine
Harvard Medical School
Boston, Massachusetts

David R Spigel, MD
Chief Scientific Officer
Program Director, Lung Cancer Research
Sarah Cannon Research Institute
Nashville, Tennessee

Project Chair

Neil Love, MD
President
Research To Practice
Miami, Florida